Ubs Group Ag Veracyte, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Veracyte, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 180,772 shares of VCYT stock, worth $7.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

180,772

Previous 154,555 16.96%

Holding current value

$7.16 Million

Previous $3.35 Million 83.67%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$21.0 - $35.25 $550,557 - $924,149	26,217 Added 16.96%	180,772 $6.15 Million
Q2 2024 Aug 13, 2024	SELL	$18.86 - $23.55 $1.56 Million - $1.95 Million	-82,593 Reduced 34.83%	154,555 $3.35 Million
Q1 2024 May 13, 2024	BUY	$21.0 - $29.1 $1.42 Million - $1.97 Million	67,539 Added 39.82%	237,148 $5.26 Million
Q4 2023 Feb 09, 2024	BUY	$19.72 - $28.68 $1.78 Million - $2.6 Million	90,483 Added 114.35%	169,609 $4.67 Million
Q3 2023 Nov 09, 2023	BUY	$22.33 - $29.92 $1.53 Million - $2.05 Million	68,570 Added 649.58%	79,126 $1.77 Million
Q2 2023 Aug 11, 2023	SELL	$20.96 - $26.99 $1.82 Million - $2.34 Million	-86,664 Reduced 89.14%	10,556 $268,000
Q1 2023 May 12, 2023	SELL	$20.58 - $27.89 $2.22 Million - $3.01 Million	-107,993 Reduced 52.62%	97,220 $2.17 Million
Q4 2022 Feb 08, 2023	BUY	$15.31 - $29.94 $2.31 Million - $4.51 Million	150,620 Added 275.9%	205,213 $4.87 Million
Q3 2022 Nov 10, 2022	SELL	$16.58 - $27.9 $403,308 - $678,667	-24,325 Reduced 30.82%	54,593 $906,000
Q2 2022 Aug 10, 2022	SELL	$15.45 - $29.52 $1.57 Million - $3 Million	-101,588 Reduced 56.28%	78,918 $1.57 Million
Q1 2022 May 16, 2022	BUY	$21.94 - $42.51 $1.98 Million - $3.83 Million	90,103 Added 99.67%	180,506 $4.98 Million
Q4 2021 Feb 14, 2022	BUY	$36.09 - $53.79 $3 Million - $4.47 Million	83,051 Added 1129.64%	90,403 $3.72 Million
Q3 2021 Nov 15, 2021	SELL	$35.62 - $52.97 $46,626 - $69,337	-1,309 Reduced 15.11%	7,352 $342,000
Q2 2021 Aug 13, 2021	BUY	$32.94 - $56.62 $137,425 - $236,218	4,172 Added 92.94%	8,661 $346,000
Q1 2021 May 12, 2021	BUY	$44.47 - $81.38 $60,746 - $111,165	1,366 Added 43.74%	4,489 $241,000
Q4 2020 Feb 11, 2021	SELL	$32.49 - $61.88 $149,064 - $283,905	-4,588 Reduced 59.5%	3,123 $153,000
Q3 2020 Nov 12, 2020	BUY	$26.73 - $35.67 $22,346 - $29,820	836 Added 12.16%	7,711 $251,000
Q2 2020 Jul 31, 2020	SELL	$19.49 - $28.11 $1.04 Million - $1.5 Million	-53,261 Reduced 88.57%	6,875 $178,000
Q1 2020 May 01, 2020	BUY	$16.13 - $30.17 $612,439 - $1.15 Million	37,969 Added 171.29%	60,136 $1.46 Million
Q4 2019 Feb 14, 2020	SELL	$20.78 - $29.99 $1.37 Million - $1.98 Million	-66,056 Reduced 74.87%	22,167 $619,000
Q3 2019 Nov 14, 2019	BUY	$23.87 - $30.93 $1.22 Million - $1.58 Million	51,054 Added 137.36%	88,223 $2.12 Million
Q2 2019 Aug 14, 2019	BUY	$22.1 - $28.56 $786,295 - $1.02 Million	35,579 Added 2237.67%	37,169 $1.06 Million
Q1 2019 May 14, 2019	SELL	$12.0 - $25.76 $24 - $51	-2 Reduced 0.13%	1,590 $40,000
Q4 2018 Feb 14, 2019	SELL	$9.15 - $14.85 $32,729 - $53,118	-3,577 Reduced 69.2%	1,592 $20,000
Q3 2018 Nov 14, 2018	SELL	$9.55 - $12.64 $32,899 - $43,544	-3,445 Reduced 39.99%	5,169 $49,000
Q2 2018 Aug 14, 2018	BUY	$5.39 - $9.66 $32,954 - $59,061	6,114 Added 244.56%	8,614 $80,000
Q1 2018 May 15, 2018	BUY	$5.44 - $6.97 $4,085 - $5,234	751 Added 42.94%	2,500 $14,000
Q4 2017 Feb 14, 2018	BUY	$6.05 - $9.37 $2,710 - $4,197	448 Added 34.44%	1,749 $11,000
Q3 2017 Nov 14, 2017	SELL	$7.81 - $8.77 $10,730 - $12,049	-1,374 Reduced 51.36%	1,301 $11,000
Q2 2017 Aug 14, 2017	BUY	N/A	777 Added 40.94%	2,675 $22,000
Q1 2017 Nov 14, 2017	BUY	N/A	1,898	1,898 $18,000

Others Institutions Holding VCYT

# of Institutions

308

Shares Held

81.8M

Call Options Held

134K

Put Options Held

13.3K

View Full List

About VERACYTE, INC.

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.83B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

More about VCYT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account